FSA
Franklin Street Advisors Portfolio holdings
AUM
$1.61B
This Quarter Return
+11.95%
1 Year Return
+24.37%
3 Year Return
+112.05%
5 Year Return
+186.1%
10 Year Return
+475.68%
AUM
$929M
AUM Growth
+$929M
(+10%)
Cap. Flow
+$51.7M
Cap. Flow
% of AUM
5.57%
Top 10 Holdings %
Top 10 Hldgs %
37.66%
Holding
156
New
14
Increased
51
Reduced
51
Closed
10
Top Buys
| 1 |
Pfizer
PFE
|
$6.57M |
| 2 |
PARA
Paramount Global Class B
PARA
|
$5.66M |
| 3 |
United Parcel Service
UPS
|
$3.84M |
| 4 |
Thermo Fisher Scientific
TMO
|
$3.78M |
| 5 |
Cummins
CMI
|
$1.73M |
Top Sells
| 1 |
AT&T
T
|
$4.69M |
| 2 |
Apple
AAPL
|
$4.64M |
| 3 |
Bristol-Myers Squibb
BMY
|
$3.94M |
| 4 |
Perrigo
PRGO
|
$2.15M |
| 5 |
Medtronic
MDT
|
$2.13M |
Sector Composition
| 1 | Technology | 25.85% |
| 2 | Healthcare | 15.19% |
| 3 | Financials | 14.38% |
| 4 | Consumer Discretionary | 12.37% |
| 5 | Communication Services | 9.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Protagonist Therapeutics
PTGX
$3.62B
| $435K | 0.05% |
22,250
-1,050
| -5% | -$20.5K |
|
102
Nektar Therapeutics
NKTR
$543M
| $423K | 0.05% |
25,500
-2,500
| -9% | -$41.6K |
|
103
Dow Inc
DOW
$17B
| $421K | 0.05% |
8,946
+200
| +2% | +$9.41K |
|
104
FibroGen
FGEN
$48.4M
| $411K | 0.04% |
10,000
| – | – |
|
|
CALA
105
DELISTED
Calithera Biosciences, Inc
CALA
| $388K | 0.04% |
112,580
| – | – |
|
106
Abbott
ABT
$230B
| $382K | 0.04% |
3,511
+670
| +24% | +$72.9K |
|
107
ScottsMiracle-Gro
SMG
$3.48B
| $373K | 0.04% |
2,440
+190
| +8% | +$29K |
|
108
Constellation Brands
STZ
$25.8B
| $352K | 0.04% |
1,855
-270
| -13% | -$51.2K |
|
109
DuPont de Nemours
DD
$31.6B
| $338K | 0.04% |
6,085
| – | – |
|
110
Blackstone
BX
$131B
| $313K | 0.03% |
+6,000
| New | +$313K |
|
111
Truist Financial
TFC
$59.8B
| $307K | 0.03% |
8,074
-1,103
| -12% | -$41.9K |
|
112
Capital One
COF
$142B
| $299K | 0.03% |
4,154
+154
| +4% | +$11.1K |
|
|
SBR
113
Sabine Royalty Trust
SBR
$1.09B
| $293K | 0.03% |
10,081
| – | – |
|
114
Bank of America
BAC
$371B
| $289K | 0.03% |
12,004
-4,380
| -27% | -$105K |
|
115
ProQR Therapeutics
PRQR
$256M
| $287K | 0.03% |
60,000
| – | – |
|
116
Goldman Sachs
GS
$221B
| $286K | 0.03% |
+1,425
| New | +$286K |
|
117
FedEx
FDX
$53.2B
| $277K | 0.03% |
+1,103
| New | +$277K |
|
118
Masco
MAS
$15.1B
| $273K | 0.03% |
4,950
| – | – |
|
|
119
Perrigo
PRGO
$3.21B
| $265K | 0.03% |
5,779
-46,972
| -89% | -$2.15M |
|
120
Unilever
UL
$158B
| $262K | 0.03% |
+4,245
| New | +$262K |
|
121
Agilent Technologies
A
$35.5B
| $260K | 0.03% |
2,575
| – | – |
|
122
BioCryst Pharmaceuticals
BCRX
$1.74B
| $258K | 0.03% |
75,000
| – | – |
|
123
Kimberly-Clark
KMB
$42.5B
| $249K | 0.03% |
1,689
+14
| +0.8% | +$2.06K |
|
124
Quest Diagnostics
DGX
$20.1B
| $245K | 0.03% |
2,143
+36
| +2% | +$4.12K |
|
|
FPRX
125
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $235K | 0.03% |
50,000
| – | – |
|